TSHEKEDI DENNIS: Open Payments
NPI 1215015508 · HUNTINGTON BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,736 in 227 payments from 13 companies in 2025. Trend: 2023 $4,659 · 2024 $4,711 · 2025 $5,736
Food & beverage: $5,730Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 52 | $1,349 |
| Janssen Pharmaceuticals, Inc | 22 | $765 |
| Luye Pharma (USA) Ltd. | 33 | $674 |
| Vanda Pharmaceuticals Inc. | 26 | $630 |
| Alkermes, Inc. | 17 | $472 |
| Teva Pharmaceuticals USA, Inc. | 26 | $444 |
| E.R. Squibb & Sons, L.L.C. | 15 | $433 |
| Otsuka America Pharmaceutical, Inc. | 9 | $308 |
| Axsome Therapeutics, Inc. | 10 | $268 |
| ABBVIE INC. | 9 | $211 |
Products named: INGREZZA, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE, FANAPT, COBENFY, AUSTEDO XR, ARISTADA, Auvelity.
Industry payments across CA — which companies pay providers there.
